EKF Diagnostics maintains expectations after first half

(Sharecast News) - EKF Diagnostics said in an update on Monday that it made good progress in the first half of 2025, with strong operational performance and a continued focus on cash generation and margin improvement. The AIM-traded diagnostics group confirmed that trading remained in line with expectations for the full year.

It highlighted growth in its core life sciences division, driven by increasing demand for enzymes used in diagnostic and vaccine manufacturing.

The firm also noted margin gains supported by operational efficiencies and a more favourable product mix.

Cash generation remained strong, with net cash of £14.4m as at 30 June, up from £12.1m at the end of December.

EKF added that it was continuing to invest in its fermentation capacity at its south Wales facility to support future demand, and expects further revenue benefits to come through in the second half of the year as new contracts are fulfilled.

CEO Mike Salter said the company remained focused on disciplined cost control and organic growth in its life sciences operations.

He added that the board remained confident in delivering full-year results in line with market expectations.

The group said it would report its interim results for the six months ended 30 June on 17 September.

At 1135 BST, shares in EKF Diagnostics Holdings were up 3.4% at 27.4p.

Reporting by Josh White for Sharecast.com.